Acute Myeloid Leukaemia

Leukaemia
#Acute Myeloid Leukaemia #Cancer research #Drug delivery

Potential treatment for patients with acute myeloid leukaemia 

Ellipses Pharma, a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, has been granted Orphan Drug Designation (ODD) by the FDA for EP0042, a dual FLT-3 and Aurora kinase inhibitor, for the treatment of acute myeloid leukaemia… Read More

#Cancer Research #News

Acute myeloid leukaemia
#Acute Myeloid Leukaemia #Biopharmaceuticals #Clinical trials #Drug development

Initially positive findings from AML treatment study 

A study by Ellipses Pharma, a global drug development company focused on accelerating the development of new oncology treatments, has presented preliminary data from the first in human Phase I/II trial of EP0042, a dual FLT-3 an Aurora kinase inhibitor, in patients with acute myeloid leukaemia (AML). … Read More

#News

Cancer cells
#Acute Myeloid Leukaemia #Cancer research #Cell and gene therapy #Clinical trials #Gene editing

First AML patient successfully transplanted with investigational drug 

Vor Bio, a clinical-stage cell and genome engineering company, has announced initial clinical data from VBP101, its Phase I/IIa multicentre, open-label, first-in-human study of tremtelectogene empogeditemcel or “trem-cel” (formerly VOR33) in patients with acute myeloid leukaemia (AML).   The data observed from the first treated patient support the… Read More

#Cancer Research #News

#Acute Myeloid Leukaemia #Blood cancer #Cancer research #Investment #Leukaemia #Plecoid

Pleco Therapeutics raises €17.3m to progress leukaemia drug

Pleco Therapeutics BV has raised €17.3 million in its Series A financing round, which will be used to complete the development of its Plecoid Product, PTX-061, to improve the effectiveness of chemotherapy in patients with acute myeloid leukaemia (AML). The investments include €3.6 million committed by Oost NL and a… Read More

#News